145 related articles for article (PubMed ID: 18074510)
1. [Prediction of adverse drug reactions based on genomic information].
Sawada J; Saito Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():16-21. PubMed ID: 18074510
[No Abstract] [Full Text] [Related]
2. [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Saito Y
Yakugaku Zasshi; 2011 Feb; 131(2):239-46. PubMed ID: 21297369
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
Mani S
AAPS PharmSci; 2001; 3(3):3. PubMed ID: 11783425
[No Abstract] [Full Text] [Related]
4. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
[No Abstract] [Full Text] [Related]
5. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
Giovannetti E; Tibaldi C; Falcone A; Danesi R; Peters GJ
J Clin Oncol; 2010 May; 28(14):e221-2; author reply e223-5. PubMed ID: 20351322
[No Abstract] [Full Text] [Related]
6. Cancer pharmacogenomics: current and future applications.
Watters JW; McLeod HL
Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan in small-cell lung cancer.
Ando Y; Figg WD
N Engl J Med; 2002 May; 346(18):1414-5; author reply 1414-5. PubMed ID: 11986422
[No Abstract] [Full Text] [Related]
8. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
9. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
10. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan pharmacogenomics.
Marsh S; Hoskins JM
Pharmacogenomics; 2010 Jul; 11(7):1003-10. PubMed ID: 20602618
[TBL] [Abstract][Full Text] [Related]
12. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
14. Insights, challenges, and future directions in irinogenetics.
Kim TW; Innocenti F
Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
[TBL] [Abstract][Full Text] [Related]
15. Barking up the wrong genome--we are not alone.
Li-Wan-Po A; Farndon P
J Clin Pharm Ther; 2011 Apr; 36(2):125-7. PubMed ID: 21366639
[TBL] [Abstract][Full Text] [Related]
16. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T
Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Sun W; Haller D
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):16-9. PubMed ID: 14569842
[TBL] [Abstract][Full Text] [Related]
18. Irinogenetics: what is the right star?
Innocenti F; Vokes EE; Ratain MJ
J Clin Oncol; 2006 May; 24(15):2221-4. PubMed ID: 16636339
[No Abstract] [Full Text] [Related]
19. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q
Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720
[TBL] [Abstract][Full Text] [Related]
20. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Satoh Y; Takai D; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Mohri D; Kawakubo K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tada M; Yatomi Y; Koike K
Cancer Chemother Pharmacol; 2013 Jan; 71(1):85-92. PubMed ID: 23053265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
